Dr. Iwuchukwu and the Ochsner Clinical Foundation are the first to clinically evaluate the new version of the Lucid Robotic System. The first generation of the Lucid Robotic System was cleared by the U.S. Food and Drug Administration in 2018, and Dr. Iwuchukwu and the Ochsner Clinical Foundation have been using an investigational version of the device within the CODEX Study System to gather and further explore the technical feasibility of the novel technology in a wide range of patients and neurological pathologies where the monitoring of cerebral blood flow velocities (CBFV) would be of benefit to stroke clinicians.
“We are grateful to be able to continue our partnership with Dr. Iwuchukwu and the Ochsner Clinical Foundation in the evaluation of our next-generation Lucid Robotic System,” said Robert Hamilton, Ph.D., co-founder and chief science officer of Neural Analytics. “This milestone represents our continued commitment to providing the clinical community with critical tools to evaluate suspected stroke patients using our robotic, autonomous and non-invasive patient management platform.”
Each year, neurological diseases cost the U.S. healthcare system nearly $800 billion.2 Traumatic brain injury, migraine, Alzheimer’s and stroke account for more than $438 billion of that cost.1 Stroke affects more than 795,000 people in the U.S.; someone has a stroke every 40 seconds, and someone dies from stroke every four minutes.2 It is a time-sensitive disease and requires intervention within 24 hours of onset of symptoms.3 Incorrect assessment of large vessel stroke leads to misdiagnosis and treatment delays, resulting in death or disability for stroke patients. Despite recent advances in life-saving treatments for acute ischemic stroke, less than five percent of stroke patients qualify for intervention because they do not present early enough.4 The American Heart Association/American Stroke Association Guidelines for Early Management of Acute Ischemic Stroke state that detection of large vessel occlusion by means of noninvasive intracranial vascular imaging greatly improves the ability to make appropriate clinical decisions.5